Future Focus: OSR Holdings, Inc. (OSRH) owns promising developmental platform technologies that address the sizable cancer immunotherapy and degenerative disease markets plus a largely de-risked, revenue-producing medical device distribution/4th party logistics (4PL) business. Moreover, with its expected pending Woori IO acquisition, the future is potentially bright indeed. Investors significantly sold off OSRH shares in early 2025 on a market maker dispute, ELOC dilution, and potential naked short selling (unrelated to fundamentals). We now focus on the future. If management grows 4PL revenue in RMC, profitably integrates Woori IO, and successfully develops its clinical and preclinical candidates, price upside is substantial.
